Literature DB >> 29472355

Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab.

Yesim Dargaud1,2, Anne Lienhart3, Maissaa Janbain4, Sandra Le Quellec3,2, Nathalie Enjolras2, Claude Negrier3,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29472355      PMCID： PMC5865419          DOI： 10.3324/haematol.2017.185330

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Insights from factor IX activation studies with chromogenic assays: implications of disparate product results.

Authors:  T W Barrowcliffe
Journal:  Haemophilia       Date:  2010-07       Impact factor: 4.287

2.  Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.

Authors:  H Luna-Záizar; C P Beltrán-Miranda; M A Esparza-Flores; J Soto-Padilla; A Bergés-García; M D C Rodríguez-Zepeda; M T Pompa-Garza; A R Jaloma-Cruz
Journal:  Haemophilia       Date:  2014-01       Impact factor: 4.287

3.  Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery.

Authors:  Yesim Dargaud; Anne Lienhart; Claude Negrier
Journal:  Blood       Date:  2010-09-01       Impact factor: 22.113

4.  A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.

Authors:  Naoki Uchida; Takehiko Sambe; Koichiro Yoneyama; Naoki Fukazawa; Takehiko Kawanishi; Shinichi Kobayashi; Midori Shima
Journal:  Blood       Date:  2015-12-01       Impact factor: 22.113

Review 5.  Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?

Authors:  Peter J Lenting; Cécile V Denis; Olivier D Christophe
Journal:  Blood       Date:  2017-10-17       Impact factor: 22.113

6.  Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH.

Authors:  Y Dargaud; A S Wolberg; E Gray; C Negrier; H C Hemker
Journal:  J Thromb Haemost       Date:  2017-06-28       Impact factor: 5.824

Review 7.  Hemophilia. Strategies for the treatment of inhibitor patients.

Authors:  J Ingerslev
Journal:  Haematologica       Date:  2000-10       Impact factor: 9.941

8.  Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision.

Authors:  Y Dargaud; A Lienhart; S Meunier; O Hequet; H Chavanne; V Chamouard; S Marin; C Negrier
Journal:  Haemophilia       Date:  2005-09       Impact factor: 4.287

Review 9.  Treatment of the bleeding inhibitor patient.

Authors:  Jan Astermark
Journal:  Semin Thromb Hemost       Date:  2003-02       Impact factor: 4.180

10.  Measurement of factor IX activity in plasma-derived and recombinant concentrates: insights from thrombin generation and activation-based assays.

Authors:  Y Yu; C M Millar
Journal:  J Thromb Haemost       Date:  2014-01       Impact factor: 5.824
View more
  13 in total

1.  Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement.

Authors:  Elena Santagostino; Maria Elisa Mancuso; Cristina Novembrino; Luigi Piero Solimeno; Armando Tripodi; Flora Peyvandi
Journal:  Haematologica       Date:  2019-03-28       Impact factor: 9.941

Review 2.  Position paper on laboratory testing for patients with haemophilia. A consensus document from SISET, AICE, SIBioC and SIPMeL.

Authors:  Armando Tripodi; Rita C Santoro; Sophie Testa; Angelo C Molinari; Sergio Bernardini; Maria Golato; Giuseppe Lippi; Walter Ageno; Elena Santagostino
Journal:  Blood Transfus       Date:  2019-02-04       Impact factor: 3.443

3.  Emicizumab should be prescribed independent of immune tolerance induction.

Authors:  Sandra Le Quellec; Claude Negrier
Journal:  Blood Adv       Date:  2018-10-23

Review 4.  Laboratory monitoring of hemophilia A treatments: new challenges.

Authors:  Peter J Lenting
Journal:  Blood Adv       Date:  2020-05-12

5.  Successful treatment of acquired hemophilia A associated with immune thrombocytopenia and joint hemarthrosis: A case report and literature review.

Authors:  Fang Wei
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

6.  Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays.

Authors:  Hande Kizilocak; Clara Lana Yukhtman; Elizabeth Marquez-Casas; Jeanie Lee; Jennifer Donkin; Guy Young
Journal:  Ther Adv Hematol       Date:  2019-06-27

Review 7.  Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.

Authors:  Georg Gelbenegger; Christian Schoergenhofer; Paul Knoebl; Bernd Jilma
Journal:  Thromb Haemost       Date:  2020-07-27       Impact factor: 5.249

Review 8.  Bispecific Antibodies and Advances in Non-Gene Therapy Options in Hemophilia.

Authors:  Midori Shima
Journal:  Res Pract Thromb Haemost       Date:  2020-04-28

9.  Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors.

Authors:  Hans H Brackmann; Wolfgang Schramm; Johannes Oldenburg; Viridiana Cano; Peter L Turecek; Claude Négrier
Journal:  Hamostaseologie       Date:  2020-07-27       Impact factor: 2.145

10.  Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation.

Authors:  Lars L F G Valke; Laura H Bukkems; Wideke Barteling; Britta A P Laros-van Gorkom; Nicole M A Blijlevens; Ron A A Mathôt; Waander L van Heerde; Saskia E M Schols
Journal:  J Thromb Haemost       Date:  2020-10-21       Impact factor: 16.036
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.